James R. Gavin III, MD, PhD - The Contemporary Use of GLP-1 RAs to Individualize Therapy in T2DM: Candid Conversations on Glycemic and Nonglycemic Effects

PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast

Go online to PeerView.com/QAM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a preeminent drug class for treating type 2 diabetes mellitus (T2DM). Mounting evidence from cardiovascular outcomes trials elevated these agents’ position in clinical guidelines because of their ability to reduce cardiovascular and renal risks, while also improving glycemic control without the burdens of hypoglycemia or weight gain. In this activity, based on a recent live web broadcast, Dr. James R. Gavin III, welcomes special guests Dr. Jens Juul Holst and Davida F. Kruger for candid conversations about the science behind GLP-1 RAs and its translation into patient-centered approaches for managing T2DM. Upon completion of this accredited CE activity, participants should be better able to: Explain the rationale for the prioritization of GLP-1 RAs in current clinical guidelines for patients with T2DM, including in patients with cardiovascular or renal disease, Compare and contrast GLP-1 RAs in terms of mechanism of action, safety, efficacy, mode of administration, and glycemic and nonglycemic effects, Engage in shared decision-making with patients with T2DM to individualize therapy with GLP-1 RAs, overcome administration barriers, and improve adherence, Incorporate GLP-1 RAs into evidence-based, individualized treatment regimens as appropriate for patients with T2DM.